CON: “Lifetime Use” Is an Awfully Long Time

Edward V. Loftus Jr.
July 2005
American Journal of Gastroenterology;Jul2005, Vol. 100 Issue 7, p1435
Academic Journal
The article focuses on the finding that infliximab has revolutionized the treatment of Crohn's disease. The dramatic and rapid clinical responses seen among many patients receiving infliximab for the first time heightened our initial enthusiasm for infliximab therapy; however, this was tempered to some degree by several observations in the first several years of commercial availability. First of all, some patients who had received infliximab early in clinical trials, had a prolonged drug-free hiatus, and then received the drug when it was commercially available, developed delayed hypersensitivity reactions consisting of fever and arthralgias.


Related Articles

  • Adalimumab in Crohn's Disease.  // BioDrugs;2007, Vol. 21 Issue 2, p133 

    The article presents the author's views regarding the use of adalimumab for treatment of patients with Crohn's disease. He mentions that based on the results of several clinical trials, the efficacy, safety and tolerability of adalimumab appears similar to that of infliximab, but with the...

  • Infliximab in Crohn's Disease: First Anniversary Clinical Experience. Cohen, Russell D.; Tsang, Jennifer F.; Hanauer, Stephen B. // American Journal of Gastroenterology;Dec2000, Vol. 95 Issue 12, p3469 

    OBJECTIVE: The aim of this study is to report on the first year experience with infliximab for Crohn's disease. METHODS: All Crohn's patients receiving infliximab at our institution in the first year of release were prospectively registered. Disease activity was scored at initial infusion, and...

  • Individualized Therapy Is a Long-Term Cost-Effective Method Compared to Dose Intensification in Crohn's Disease Patients Failing Infliximab. Steenholdt, Casper; Brynskov, Jørn; Thomsen, Ole; Munck, Lars; Fallingborg, Jan; Christensen, Lisbet; Pedersen, Gitte; Kjeldsen, Jens; Jacobsen, Bent; Oxholm, Anne; Kjellberg, Jakob; Bendtzen, Klaus; Ainsworth, Mark // Digestive Diseases & Sciences;Sep2015, Vol. 60 Issue 9, p2762 

    Background: In Crohn's disease patients failing infliximab therapy, interventions defined by an algorithm based on infliximab and anti-infliximab antibody measurements have proven more cost-effective than intensifying the infliximab regimen. Aim: This study investigated long-term economic...

  • Relationship between serum infliximab trough levels and endoscopic activities in patients with Crohn's disease under scheduled maintenance treatment. Imaeda, Hirotsugu; Bamba, Shigeki; Takahashi, Kenichiro; Fujimoto, Takehide; Ban, Hiromitsu; Tsujikawa, Tomoyuki; Sasaki, Masaya; Fujiyama, Yoshihide; Andoh, Akira // Journal of Gastroenterology;Apr2014, Vol. 49 Issue 4, p674 

    Background and aims: Few data are available to support the clinical relevance of infliximab (IFX) trough levels for prediction of endoscopic disease activity in Crohn's disease (CD). This study evaluated the endoscopic disease activities in relation to clinical outcome using several laboratory...

  • PRO: Maintenance Therapy Is Superior to Episodic Therapy. Lichtenstein, Gary R. // American Journal of Gastroenterology;Jul2005, Vol. 100 Issue 7, p1433 

    The article debates on the use if infliximab in the treatment of Crohn's disease. The primary goals of pharmacological intervention in Crohn's disease are to improve the patient's quality of life, reduce the risk of Crohn's disease-related complications and avoid surgical intervention. The...

  • Genital condylomata in a patient receiving infliximab for crohn's disease. Somasekar, A.; Alcolado, R. // Postgraduate Medical Journal;Jun2004, Vol. 80 Issue 944, p358 

    Infliximab is a rnonoclonol antibody against tumour necrosis factor-alpha. Recent studies have shown that it is effective in treating patients with refractory Crohn's disease and in those with Crahn's fistulae. Though this drug is found to be safe in clinical trials, sporadic reports of serious...

  • Factors Associated with the Development of Intestinal Strictures or Obstructions in Patients with Crohn's Disease. Lichtenstein, Gary R.; Olson, Allan; Travers, Suzanne; Diamond, Robert H.; Chen, Donny M.; Pritchard, Michelle L.; Feagan, Brian G.; Cohen, Russell D.; Salzberg, Bruce A.; Hanauer, Stephen B.; Sandborn, William J. // American Journal of Gastroenterology;May2006, Vol. 101 Issue 5, p1030 

    OBJECTIVE: Theoretical concern exists that rapid luminal healing in Crohn's disease (CD) with therapies like infliximab increases the risk of intestinal stenosis, stricture, or obstruction (SSOs). METHODS: Data were analyzed from the ongoing observational TREAT (the Crohn's Therapy, Resource,...

  • Potential therapeutic role for cytokine or adhesion molecule manipulation in Crohn's disease: in the shadow of infliximab? Shand, Alan; Forbes, Alastair // International Journal of Colorectal Disease;Jan2003, Vol. 18 Issue 1, p1 

    Background. Inappropriate activation of the intestinal immune system leading to a persistent inflammatory response is implicated in the pathogenesis of both Crohn's disease and ulcerative colitis. Various cytokines and cell surface molecules expressed by immunologically active cells are involved...

  • Secondary Amyloidosis in a Patient with Long Duration Crohn's Disease Treated with Infliximab.  // BioDrugs;2010 Supplement 1, Vol. 24, p15 

    No abstract available.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics